Tvardi Therapeutics Files 8-K
Ticker: TVRD · Form: 8-K · Filed: May 27, 2025 · CIK: 1346830
| Field | Detail |
|---|---|
| Company | Tvardi Therapeutics, Inc. (TVRD) |
| Form Type | 8-K |
| Filed Date | May 27, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, company-update
TL;DR
Tvardi Therapeutics filed an 8-K on 5/27/25. Check it for financials.
AI Summary
Tvardi Therapeutics, Inc. filed an 8-K on May 27, 2025, reporting on financial statements and exhibits. The company, formerly known as Cara Therapeutics, Inc., is incorporated in Delaware and headquartered in Sugar Land, Texas.
Why It Matters
This filing provides official updates on Tvardi Therapeutics' financial and exhibit information, which is crucial for investors to assess the company's current status.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate operational or financial distress.
Key Players & Entities
- Tvardi Therapeutics, Inc. (company) — Registrant
- Cara Therapeutics, Inc. (company) — Former company name
- May 27, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Sugar Land, Texas (location) — Principal executive office address
FAQ
What is the primary purpose of this 8-K filing for Tvardi Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on financial statements and exhibits as of May 27, 2025.
When was Tvardi Therapeutics, Inc. incorporated?
Tvardi Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address for Tvardi Therapeutics, Inc.?
The principal executive office address is 3 Sugar Creek Ctr. Blvd. Suite 525, Sugar Land, Texas 77478.
Has Tvardi Therapeutics, Inc. operated under any former names?
Yes, Tvardi Therapeutics, Inc. was formerly known as Cara Therapeutics, Inc.
What is the SEC file number for Tvardi Therapeutics, Inc.?
The SEC file number for Tvardi Therapeutics, Inc. is 001-36279.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 27, 2025 regarding Tvardi Therapeutics, Inc. (TVRD).